$TRUP
TRUPANION, INC. Stock $trup

$trup Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000137128524000120 Filed on May 03, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue	$314.8M	$306.1M	$295.9M
YoY Change	16.35%	19.43%	20.26%
Cost Of Revenue	$274.5M	$269.9M	$255.8M
YoY Change	13.82%	17.35%	20.45%
Gross Profit	$40.27M	$36.23M	$40.06M
YoY Change	37.1%	37.5%	19.06%
Gross Profit Margin	12.79%	11.83%	13.54%
Selling, General & Admin	$33.13M	$31.52M	$30.58M
YoY Change	-2.29%	-26.12%	-7.42%
% of Gross Profit	82.26%	87.0%	76.33%
Research & Development	$8.190M	$6.960M	$5.969M
YoY Change	56.54%	42.04%	-14.18%
% of Gross Profit	20.34%	19.21%	14.9%
Depreciation & Amortization	$4.376M	$3.785M	$3.024M
YoY Change	34.52%	18.21%	4.38%
% of Gross Profit	10.87%	10.45%	7.55%
Operating Expenses	$45.69M	$42.26M	$39.58M
YoY Change	7.79%	-16.75%	-7.71%
Operating Profit	-$5.471M	-$6.137M	$487.0K
YoY Change	-58.2%	-74.94%	-105.28%
Interest Expense	$3.655M	$3.596M	-$3.776M
YoY Change	24.32%	50.65%	125.84%
% of Operating Profit			-775.36%
Other Income/Expense, Net	$3.220M	$2.843M	$1.256M
YoY Change	54.96%	49.47%	-16.49%
Pretax Income	-$5.906M	-$6.890M	-$2.033M
YoY Change	-57.67%	-72.41%	-78.14%
Income Tax	-$44.00K	-$38.00K	$130.0K
% Of Pretax Income
Net Earnings	-$5.862M	-$6.852M	-$2.163M
YoY Change	-57.26%	-72.35%	-76.7%
Net Earnings / Revenue	-1.86%	-2.24%	-0.73%
Basic Earnings Per Share	-$0.14	-$0.16
Diluted Earnings Per Share	-$0.14	-$0.16	-$0.05
COMMON SHARES
Basic Shares Outstanding	42.02M shares	41.81M shares	41.55M shares
Diluted Shares Outstanding	42.08M shares	41.92M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$277.2M	$275.2M	$277.2M
YoY Change	17.43%	12.49%	24.62%
Cash & Equivalents	$124.3M	$146.5M	$147.5M
Short-Term Investments	$152.9M	$128.7M	$129.7M
Other Short-Term Assets	$15.70M	$17.08M	$17.02M
YoY Change	-16.84%	-2.33%	19.47%
Inventory
Prepaid Expenses
Receivables	$285.9M	$278.5M	$267.9M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$578.9M	$570.8M	$562.1M
YoY Change	11.19%	11.84%	19.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$104.0M	$104.4M	$103.7M
YoY Change	6.16%	10.47%	14.28%
Goodwill	$43.03M	$42.98M	$43.71M
YoY Change	-1.93%	-0.11%	4.12%
Intangibles	$15.93M	$17.22M	$18.75M
YoY Change	-26.36%	-25.2%	-22.0%
Long-Term Investments	$14.12M	$13.01M	$300.0K
YoY Change	43.81%	54.11%	0.0%
Other Assets	$16.74M	$18.01M	$18.92M
YoY Change	-7.8%	-7.83%	-0.11%
Total Long-Term Assets	$217.1M	$218.7M	$220.9M
YoY Change	3.57%	5.37%	9.05%
TOTAL ASSETS
Total Short-Term Assets	$578.9M	$570.8M	$562.1M
Total Long-Term Assets	$217.1M	$218.7M	$220.9M
Total Assets	$795.9M	$789.5M	$782.9M
YoY Change	9.01%	9.97%	16.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.630M	$8.348M	$10.51M
YoY Change	-4.16%	13.06%	10.92%
Accrued Expenses	$34.67M	$30.47M	$34.05M
YoY Change	15.97%	3.09%	4.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.350M	$1.350M	$1.350M
YoY Change	22.73%	6.89%	22.39%
Total Short-Term Liabilities	$355.8M	$351.6M	$344.5M
YoY Change	7.61%	12.68%	18.94%
LONG-TERM LIABILITIES
Long-Term Debt	$127.6M	$127.5M	$127.6M
YoY Change	23.92%	23.85%	86.65%
Other Long-Term Liabilities	$4.495M	$4.627M	$4.487M
YoY Change	-8.28%	-7.9%	-9.68%
Total Long-Term Liabilities	$132.1M	$132.1M	$4.487M
YoY Change	22.46%	22.37%	-9.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$355.8M	$351.6M	$344.5M
Total Long-Term Liabilities	$132.1M	$132.1M	$4.487M
Total Liabilities	$490.1M	$486.1M	$479.2M
YoY Change	11.02%	14.89%	30.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$229.0M	-$223.1M	-$216.3M
YoY Change	9.0%	13.63%	26.05%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$16.53M	$16.53M	$16.53M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$305.8M	$303.4M	$303.7M
YoY Change
Total Liabilities & Shareholders Equity	$795.9M	$789.5M	$782.9M
YoY Change	9.01%	9.97%	16.57%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$5.862M	-$6.852M	-$2.163M
YoY Change	-57.26%	-72.35%	-76.7%
Depreciation, Depletion And Amortization	$4.376M	$3.785M	$3.024M
YoY Change	34.52%	18.21%	4.38%
Cash From Operating Activities	$6.856M	$2.434M	$17.51M
YoY Change	-301.35%	-135.47%	1618.16%
INVESTING ACTIVITIES
Capital Expenditures	$2.880M	$3.065M	$3.970M
YoY Change	-39.18%	-40.88%	-27.53%
Acquisitions
YoY Change
Other Investing Activities	-$24.84M	-$516.0K	-$13.48M
YoY Change	3028.09%	416.0%	-46.24%
Cash From Investing Activities	-$27.72M	-$2.737M	-$17.45M
YoY Change	401.3%	-108.07%	-42.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-958.0K	-$286.0K	566.0K
YoY Change	930.11%	-100.85%	-96.14%
NET CHANGE
Cash From Operating Activities	6.856M	$2.434M	17.51M
Cash From Investing Activities	-27.72M	-$2.737M	-17.45M
Cash From Financing Activities	-958.0K	-$286.0K	566.0K
Net Change In Cash	-21.82M	-$902.0K	623.0K
YoY Change	141.71%	-101.48%	-104.2%
FREE CASH FLOW
Cash From Operating Activities	$6.856M	$2.434M	$17.51M
Capital Expenditures	$2.880M	$3.065M	$3.970M
Free Cash Flow	$3.976M	-$631.0K	$13.54M
YoY Change	-148.85%	-94.76%	-403.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	trup	Claims Expense ClaimsExpense	233569000	usd
CY2023Q1	trup	Claims Expense ClaimsExpense	194137000	usd
CY2024Q1	trup	Other Costof Services Sold OtherCostofServicesSold	36325000	usd
CY2023Q1	trup	Other Costof Services Sold OtherCostofServicesSold	35846000	usd
CY2024Q1	trup	Technologyand Development Expense TechnologyandDevelopmentExpense	6960000	usd
CY2023Q1	trup	Technologyand Development Expense TechnologyandDevelopmentExpense	4900000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	269894000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	229983000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14673000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21017000	usd
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	16843000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	21642000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3785000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3202000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	42261000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	50761000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-103000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-71000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6137000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-24486000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	3596000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	2387000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2843000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1902000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6890000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24971000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-38000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-191000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6852000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24780000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41917094	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41917094	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41107889	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41107889	shares
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6852000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24780000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1332000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1555000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-652000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	491000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1984000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2046000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8836000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22734000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	146455000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	147501000	usd
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	128734000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	129667000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	1093000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	1085000	usd
CY2024Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	278492000	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	267899000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	17084000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	17022000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	570765000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	562089000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	23106000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	22963000	usd
CY2024Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	13007000	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	12866000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	104365000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	103650000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	17221000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18745000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18013000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18922000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	42983000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	43713000	usd
CY2024Q1	us-gaap	Assets Assets	789460000	usd
CY2023Q4	us-gaap	Assets Assets	782948000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	8348000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10505000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30473000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34052000	usd
CY2024Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	62275000	usd
CY2023Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	63238000	usd
CY2024Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	249135000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	235329000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	1350000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1350000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	351581000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	344474000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	127482000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	127580000	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2399000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2685000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4627000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4487000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	486089000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	479226000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43032805	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42004619	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42887052	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41858866	shares
CY2024Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	usd
CY2023Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2023Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	544593000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	536108000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1581000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	403000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-223107000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-216255000	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1028186	shares
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1028186	shares
CY2024Q1	us-gaap	Treasury Stock Value TreasuryStockValue	16534000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	16534000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	303371000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	303722000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	789460000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	782948000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	303722000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-127000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8358000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1984000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6852000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	303371000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	305297000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	713000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12959000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2046000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24780000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	294809000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6852000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24780000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3785000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3202000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8152000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	12331000	usd
CY2024Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	202000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	397000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10718000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	15847000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-287000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3765000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-5131000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-5148000	usd
CY2024Q1	trup	Increase Decreasein Claims Reserveand Loss Adjustment IncreaseDecreaseinClaimsReserveandLossAdjustment	-885000	usd
CY2023Q1	trup	Increase Decreasein Claims Reserveand Loss Adjustment IncreaseDecreaseinClaimsReserveandLossAdjustment	4606000	usd
CY2024Q1	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	13998000	usd
CY2023Q1	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	22936000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2434000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6862000	usd
CY2024Q1	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	19193000	usd
CY2023Q1	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	34795000	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	19005000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	73793000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3065000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5184000	usd
CY2024Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-516000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-100000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2737000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	33914000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	35130000	usd
CY2024Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	338000	usd
CY2023Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	607000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	372000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	140000	usd
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	245000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	853000	usd
CY2024Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-75000	usd
CY2023Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-286000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	33810000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-313000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	260000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-902000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	61122000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	170464000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84637000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	169562000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	145759000	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	694000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1243000	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	Nature of Operations and Significant Accounting Policies<div style="margin-bottom:5pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business and Basis of Presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trupanion, Inc. (collectively with its wholly-owned subsidiaries, the "Company") provides medical insurance for cats and dogs in the United States, Canada, Continental Europe, and Australia. The Company's data-driven, vertically-integrated approach enables the Company to provide pet owners with products that the Company believes are the highest value medical insurance, priced specifically for each pet’s unique characteristics. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data as of December 31, 2023 was derived from the Company's audited consolidated financial statements. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and, in management's opinion, have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company's financial position, results of operations, comprehensive income (loss), stockholders' equity and cash flows for the interim periods. These unaudited interim consolidated financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (SEC) on February 27, 2024 (the 2023 10-K). The Company's accounting policies are described in Note 1 to the audited financial statements included in the 2023 10-K. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the full fiscal year or any other interim period.</span></div><div style="margin-bottom:5pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. See Note 1 to the audited financial statements included in the 2023 10-K for additional discussion of these estimates and assumptions.</span></div>
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:5pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. See Note 1 to the audited financial statements included in the 2023 10-K for additional discussion of these estimates and assumptions.</span></div>
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	4084000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	4050000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	87440000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	87388000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost	91524000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	91438000	usd
CY2024Q1	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount	24917000	usd
CY2024Q1	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Fair Value HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue	24911000	usd
CY2024Q1	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount	998000	usd
CY2024Q1	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Fair Value HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	998000	usd
CY2024Q1	us-gaap	Held To Maturity Securities Debt Maturities Single Maturity Date Amortized Cost Basis HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	25915000	usd
CY2024Q1	us-gaap	Held To Maturity Securities Debt Maturities Single Maturity Date Fair Value HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue	25909000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	500000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	300000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	24900000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	300000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	39400000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	200000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	18900000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	200000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	25900000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	100000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	15100000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	24000000	usd
CY2021Q4	trup	Purchaseof Equity Interest PurchaseofEquityInterest	7000000	usd
CY2024Q1	us-gaap	Financing Receivable Revolving FinancingReceivableRevolving	7000000	usd
CY2024Q1	trup	Financing Receivable Revolving Annual Increase FinancingReceivableRevolvingAnnualIncrease	2000000	usd
CY2024Q1	us-gaap	Notes Receivable Net NotesReceivableNet	3300000	usd
CY2023Q4	us-gaap	Notes Receivable Net NotesReceivableNet	4000000	usd
CY2024Q1	trup	Servicesperformedfor Variable Interest Entity ServicesperformedforVariableInterestEntity	100000	usd
CY2023Q1	trup	Servicesperformedfor Variable Interest Entity ServicesperformedforVariableInterestEntity	200000	usd
CY2024Q1	us-gaap	Noncontrolling Interest In Variable Interest Entity NoncontrollingInterestInVariableInterestEntity	5326000	usd
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	203058000	usd
CY2023Q4	us-gaap	Noncontrolling Interest In Variable Interest Entity NoncontrollingInterestInVariableInterestEntity	5326000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	188745000	usd
CY2023Q4	us-gaap	Noncontrolling Interest In Variable Interest Entity NoncontrollingInterestInVariableInterestEntity	5300000	usd
CY2024Q1	us-gaap	Noncontrolling Interest In Variable Interest Entity NoncontrollingInterestInVariableInterestEntity	5300000	usd
CY2024Q1	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	0	usd
CY2023Q1	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	0	usd
CY2024Q1	us-gaap	Notes Receivable Fair Value Disclosure NotesReceivableFairValueDisclosure	6100000	usd
CY2023Q4	us-gaap	Notes Receivable Fair Value Disclosure NotesReceivableFairValueDisclosure	6800000	usd
CY2024Q1	us-gaap	Line Of Credit Facility Initiation Date1 LineOfCreditFacilityInitiationDate1	2022-03-25
CY2024Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	150000000	usd
CY2024Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.1046
CY2024Q1	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	5900000	usd
CY2024Q1	us-gaap	Line Of Credit Facility Expiration Date1 LineOfCreditFacilityExpirationDate1	2027-03-25
CY2024Q1	trup	Line Of Credit Facility Periodic Payment Principal Percentage LineOfCreditFacilityPeriodicPaymentPrincipalPercentage	0.0025
CY2024Q1	us-gaap	Line Of Credit Facility Frequency Of Payments LineOfCreditFacilityFrequencyOfPayments	quarterly
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1012000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1350000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1350000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	72113000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	57125000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	0	usd
CY2024Q1	us-gaap	Line Of Credit LineOfCredit	132950000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8152000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12331000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	206000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	628000	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	8358000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	12959000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	4800000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	408970	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.09
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6715000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	22658	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	16.41
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	338000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	386312	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.95
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5275000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	386312	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	13.95
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	5275000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42004619	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	0	shares
CY2023Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	0	shares
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-103000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-71000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6137000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-24486000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	3596000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	2387000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2843000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1902000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6890000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24971000	usd
CY2024Q1	us-gaap	Revenues Revenues	306121000	usd
CY2023Q1	us-gaap	Revenues Revenues	256329000	usd
CY2024Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	150000000	usd
CY2024Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	150000000	usd
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	true
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	true
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	true

Files In Submission

Name	View Source	Status
0001371285-24-000120-index-headers.html	Edgar Link	pending
0001371285-24-000120-index.html	Edgar Link	pending
0001371285-24-000120.txt	Edgar Link	pending
0001371285-24-000120-xbrl.zip	Edgar Link	pending
ex311q12024.htm	Edgar Link	pending
ex312q12024.htm	Edgar Link	pending
ex321q12024.htm	Edgar Link	pending
ex322q12024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trup-20240331.htm	Edgar Link	pending
trup-20240331.xsd	Edgar Link	pending
trup-20240331_def.xml	Edgar Link	unprocessable
trup-20240331_lab.xml	Edgar Link	unprocessable
trup-20240331_pre.xml	Edgar Link	unprocessable
trup-20240331_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
trup-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TRUP
TRUPANION, INC. Stock $trup

2024 Q2 Form 10-Q Financial Statement

#000137128524000120 Filed on May 03, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRUP TRUPANION, INC. Stock $trup

2024 Q2 Form 10-Q Financial Statement

#000137128524000120 Filed on May 03, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRUP
TRUPANION, INC. Stock $trup